MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
144.76
-6.28
-4.16%
After Hours: 144.76 0 0.00% 16:18 07/10 EDT
OPEN
150.39
PREV CLOSE
151.04
HIGH
150.39
LOW
140.06
VOLUME
214.96K
TURNOVER
--
52 WEEK HIGH
161.38
52 WEEK LOW
23.76
MARKET CAP
2.08B
P/E (TTM)
-34.8148
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PVLA last week (0629-0703)?
Weekly Report · 4d ago
Palvella Therapeutics director Matthew Pauls files initial beneficial ownership statement
PUBT · 07/01 20:06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)
TipRanks · 07/01 09:50
Palvella Therapeutics Adds Industry Veteran to Board
TipRanks · 06/30 11:58
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
TipRanks · 06/30 11:45
Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directors
PUBT · 06/30 11:31
PALVELLA THERAPEUTICS APPOINTS ACCOMPLISHED RARE DISEASE BIOTECH EXECUTIVE AND COMMERCIAL LEADER MATT PAULS, J.D., M.B.A., TO BOARD OF DIRECTORS
Reuters · 06/30 11:30
*Palvella Therapeutics Appoints Matt Pauls to Bd of Directors
Dow Jones · 06/30 11:30
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.